Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 6/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27523667 | 0.61 | KDM4E (0.46) | MCL1KDM4E | |
| SCHEMBL17686337 | 0.59 | MCL1 (0.70) | BCL2MCL1BCL2L1 | |
| SCHEMBL1060065 | 0.58 | CYP1A2 (0.44) | KDM4ECYP1A2 | |
| SCHEMBL27609208 | 0.56 | ALDH1A1 (0.46) | KDM4ESMN1; SMN2 | |
| SCHEMBL15841765 | 0.55 | SELL (0.38) | BCL2MCL1KDM4ESMN1; SMN2 | |
| SCHEMBL1193168 | 0.54 | CYP1A2 (0.42) | KDM4ECYP1A2 | |
| SCHEMBL24159779 | 0.54 | KAT8 (0.50) | — | |
| SCHEMBL19678683 | 0.54 | CSNK2A1 (0.46) | MCL1KDM4ESMN1; SMN2 | |
| SCHEMBL16127921 | 0.54 | CSNK2A1 (0.50) | MCL1 | |
| SCHEMBL8072439 | 0.54 | RARB (0.36) | MCL1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949965-B2 | Tricyclic indole Mcl-1 inhibitors and uses thereof | VANDERBILT UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160106731-A1 | TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106731-A1 | TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF | MCL1, BCL2L1, BCL3 | BCL2 4/4885MCL1 1/4885KDM4E 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.